Cerecor to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Summary

ROCKVILLE, Md., Aug. 5, 2020 – Cerecor (NASDAQ: CERC) announced that CEO Michael F. Cola will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 8:00 a.m. EDT. Investors can access the live webcast via the company's website.

Cerecor, focused on treating rare pediatric and orphan diseases, is advancing its clinical pipeline, including CERC-801, CERC-802, and CERC-803 for Congenital Disorders of Glycosylation, all with Rare Pediatric Disease and Orphan Drug Designations from the FDA, potentially qualifying for a Priority Review Voucher.

ROCKVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company focused on the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that Michael F. Cola, President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 8:00 a.m. EDT.

A live webcast of the presentation can be accessed under "News/Events" page in the Investors section of the Company's website at www.cerecor.com.

About Cerecor

Cerecor is a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases. The Company is advancing an emerging clinical-stage pipeline of innovative therapies. The Company’s pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (“CERC-800 programs”), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (”CDGs”). The FDA granted Rare Pediatric Disease Designation and Orphan Drug Designation (“ODD”) to all three CERC-800 programs, thus potentially qualifying the Company to receive a Priority Review Voucher (“PRV”) upon approval of a new drug application (“NDA”). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody being developed for the treatment of autoimmune inflammatory diseases such as Adult Onset Stills Disease (“AOSD”) and Multiple Myeloma (“MM”). CERC-006 is a dual mTOR inhibitor being developed for the treatment of complex Lymphatic Malformations. CERC-002 is an anti-LIGHT monoclonal antibody being developed for the treatment of COVID-19 ARDS and Pediatric-onset Crohn’s Disease.

For more information about Cerecor, please visit www.cerecor.com.

Forward-Looking Statements

This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Cerecor’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Cerecor’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: the development of product candidates or products; timing and success of trial results and regulatory review; potential attributes and benefits of product candidates; and other statements that are not historical. These statements are based upon the current beliefs and expectations of Cerecor’s management but are subject to significant risks and uncertainties, including: drug development costs, timing and other risks, including reliance on investigators and enrollment of patients in clinical trials, which might be slowed by the COVID-19 pandemic; regulatory risks; Cerecor's cash position and the need for it to raise additional capital; general economic and market risks and uncertainties, including those caused by the COVID-19 pandemic; and those other risks detailed in Cerecor’s filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Cerecor expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Cerecor’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For media and investor inquiries

James Harrell,
Investor Relations
Chief Commercial Officer
Cerecor Inc.
jharrell@cerecor.com
623.439.2220 office

FAQ

What is Cerecor's focus in the biopharmaceutical industry?

Cerecor focuses on developing treatments for rare pediatric and orphan diseases.

When will Cerecor present at the Wedbush PacGrow Healthcare Virtual Conference?

Cerecor will present on August 11, 2020, at 8:00 a.m. EDT.

What are the key products in Cerecor's pipeline?

Cerecor's pipeline includes CERC-801, CERC-802, and CERC-803, targeting Congenital Disorders of Glycosylation.

What designations have the CERC-800 programs received from the FDA?

The CERC-800 programs have received Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA.

How can investors access the live webcast of Cerecor's presentation?

Investors can access the live webcast on Cerecor's website under the 'News/Events' section.